All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the 63rd ASH Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak with Elizabeth Budde, City of Hope Comprehensive Cancer Center, Duarte, US. We asked, What results have you seen with mosunetuzumab in patients with high-risk follicular lymphoma (FL)?
What results have you seen with mosunetuzumab in patients with high-risk FL?
Budde discusses the pivotal results of a phase II trial that investigated mosunetuzumab in relapsed/refractory (R/R) FL patients, with at least 2 prior lines of therapy. She outlines the encouraging overall response rates, complete response rates, and duration of response. Finally, she summarizes that mosunetuzumab is a well tolerable treatment, with no treatment mortalities.
Follicular lymphoma: A summary of the hot topics presented at the 63rd American Society of Hematology Annual Meeting and Exposition
Follicular lymphoma (FL), a form of non-Hodgkin lymphoma, is an indolent but incurable lymphoproliferative disorder of...
Results from a phase I/Ib dose-escalation study of mosunetuzumab in high-risk non-Hodgkin lymphoma patients
During the plenary session at the 61st ASH Annual Meeting & Exposition, Stephen Schuster presented the phase I/Ib dose-escalation and...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox